Literature DB >> 35228656

Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor.

Angela D Bhalla1, Sharon M Landers1, Anand K Singh2, Jace P Landry1, Michelle G Yeagley1, Gabryella S B Myerson1, Cristian B Delgado-Baez1,3,4, Stephanie Dunnand1,4, Theresa Nguyen1, Xiaoyan Ma1, Svetlana Bolshakov1, Brian A Menegaz5, Salah-Eddine Lamhamedi-Cherradi5, Xizeng Mao2, Xingzhi Song2, Alexander J Lazar6, Ian E McCutcheon7, John M Slopis8, Joseph A Ludwig5, Dina C Lev9, Kunal Rai2, Keila E Torres10,11.   

Abstract

Undifferentiated pleomorphic sarcoma (UPS) and malignant peripheral nerve sheath tumor (MPNST) are aggressive soft tissue sarcomas that do not respond well to current treatment modalities. The limited availability of UPS and MPNST cell lines makes it challenging to identify potential therapeutic targets in a laboratory setting. Understanding the urgent need for improved treatments for these tumors and the limited cellular models available, we generated additional cell lines to study these rare cancers. Patient-derived tumors were used to establish 4 new UPS models, including one radiation-associated UPS-UPS271.1, UPS511, UPS0103, and RIS620, one unclassified spindle cell sarcoma-USC060.1, and 3 new models of MPNST-MPNST007, MPNST3813E, and MPNST4970. This study examined the utility of the new cell lines as sarcoma models by assessing their tumorigenic potential and mutation status for known sarcoma-related genes. All the cell lines formed colonies and migrated in vitro. The in vivo tumorigenic potential of the cell lines and corresponding xenografts was determined by subcutaneous injection or xenograft re-passaging into immunocompromised mice. USC060.1 and UPS511 cells formed tumors in mice upon subcutaneous injection. UPS0103 and RIS620 tumor implants formed tumors in vivo, as did MPNST007 and MPNST3813E tumor implants. Targeted sequencing analysis of a panel of genes frequently mutated in sarcomas identified TP53, RB1, and ATRX mutations in a subset of the cell lines. These new cellular models provide the scientific community with powerful tools for detailed studies of tumorigenesis and for investigating novel therapies for UPS and MPNST.
© 2022. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology.

Entities:  

Mesh:

Year:  2022        PMID: 35228656     DOI: 10.1038/s41374-022-00734-6

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  73 in total

Review 1.  Diagnosis and management of pleomorphic sarcomas (so-called "MFH") in adults.

Authors:  Alessandra F Nascimento; Chandrajit P Raut
Journal:  J Surg Oncol       Date:  2008-03-15       Impact factor: 3.454

2.  Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases.

Authors:  Domagoj A Vodanovich; Tim Spelman; Deborah May; John Slavin; Peter F M Choong
Journal:  ANZ J Surg       Date:  2019-07-30       Impact factor: 1.872

Review 3.  Soft tissue sarcomas with complex genomic profiles.

Authors:  Louis Guillou; Alain Aurias
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

4.  Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group.

Authors:  C D Fletcher; P Dal Cin; I de Wever; N Mandahl; F Mertens; F Mitelman; J Rosai; A Rydholm; R Sciot; G Tallini; H van den Berghe; R Vanni; H Willén
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

5.  Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study.

Authors:  R S Bridge; J A Bridge; J R Neff; S Naumann; P Althof; L A Bruch
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

Review 6.  The evolving classification of soft tissue tumours: an update based on the new WHO classification.

Authors:  C D M Fletcher
Journal:  Histopathology       Date:  2006-01       Impact factor: 5.087

Review 7.  Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies.

Authors:  E Wardelmann; H-U Schildhaus; S Merkelbach-Bruse; W Hartmann; P Reichardt; P Hohenberger; R Büttner
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

Review 8.  Sarcoma epidemiology and etiology: potential environmental and genetic factors.

Authors:  Guy Lahat; Alexander Lazar; Dina Lev
Journal:  Surg Clin North Am       Date:  2008-06       Impact factor: 2.741

9.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Authors:  Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

10.  Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways.

Authors:  Christopher D Steele; Maxime Tarabichi; Dahmane Oukrif; Amy P Webster; Hongtao Ye; Matthew Fittall; Patrick Lombard; Iñigo Martincorena; Patrick S Tarpey; Grace Collord; Kerstin Haase; Sandra J Strauss; Fitim Berisha; Heli Vaikkinen; Pawan Dhami; Marnix Jansen; Sam Behjati; M Fernanda Amary; Roberto Tirabosco; Andrew Feber; Peter J Campbell; Ludmil B Alexandrov; Peter Van Loo; Adrienne M Flanagan; Nischalan Pillay
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

View more
  1 in total

Review 1.  The Role of CDK Pathway Dysregulation and Its Therapeutic Potential in Soft Tissue Sarcoma.

Authors:  Johannes Tobias Thiel; Adrien Daigeler; Jonas Kolbenschlag; Katarzyna Rachunek; Sebastian Hoffmann
Journal:  Cancers (Basel)       Date:  2022-07-12       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.